Tangiamo publicerade den 28 februari 2023 bolagets delårsrapport för det fjärde kvartalet 2022.
Organic sales growth +15% y-o-y EBIT margin of 13.2% (13.
Redeye raises its forecasts and Base Case slightly following the price increases on the majority of ...
Cline Scientific AB ("Cline" eller "Bolaget") har genom en egenutvecklad och patenterad gradienttekn...
Zoomability har som ett resultat av intensifierade marknadsföringssatsningar och ett mer gynnsamt ma...
With strong clinical evidence to treat the growing problem of Sports Related Concussions (SRCs), Pol...
Rapporten för det fjärde kvartalet innehöll inga större överraskningar.
Qlosr Group växte intäkterna med 75 procent till 145 mkr i Q4:an och överträffade sitt omsättningsmå...
VBG Group avslutar 2022 starkt och levererar ett trendbrott uppåt i rörelsemarginalen i Q4:an.
Redeye comments on SDS’s Q4 results, which came in line with preliminary figures and well below our ...
Redeye provides an update in relation to RLS’ Q4 2022 report.
Redeye retains its positive view on Efecte, following a Q4 report with high growth from new sales bo...
Redeye provides an update in relation to ISAB’s Q4 2022 report.
41% organic sales growth, adj. EBITA margin 5% First report using IFRS affects goodwill and leasing ...
Redeye will cease its coverage of 2cureX, effective 1st March 2023.
Share down 20% today despite limited changes to outlook We expect positive FCF ex.
'23 guidance of 22-34% ARR growth was a positive surprise Worsening cash burn in '23e-'25e; equity i...
Redeye ceases its current coverage of Isofol Medical due to the end of the contractual period.
Redeye comments on Gasporox Q4'22 report which came in lighter than expected.
Redeye comments on Fluoguide’s Q4 2022 report as we enter a catalyst-rich 2023e for the company.
